solubility
Parallel Screening - Can you afford to miss out?
January 16 by Pharmaceuticals & Biotechnology EditorImproving the bioavailability of poorly soluble new chemical entities is a leading challenge in drug development. Discover how parallel screening can ensure rapid determination of the most app...
Novartis' Jennifer Sheng on Solubility Modelling & the Future of Solubilisation
December 10 by Andrea CharlesPoor solubility is an obvious barrier to advancing potentially efficacious drug candidates. In this interview Jennifer Sheng, Fellow at Novartis, discusses the most efficient approaches for...
Whitepaper: Phys.- Chem. Characterisation of NCEs in Pre-Formulation: Use of In silico Tools
October 10 by Pharmaceuticals & Biotechnology EditorAs solubility (or rather poor solubility) is one of the hot topics in drug development, there is a strong interest in gaining solubility data early on, at a stage of a project where there is still a...
Survey: Improving Solubility 2012
April 27 by Pharma IQ SurveysIn preparation for the 8th Annual Improving Solubility Summit, taking place in June, Pharma IQ would like to invite you to take part in a short survey. The survey consists of no more than 8 questions...
Identifying Formulations to Progress Compounds Solubility
March 20 by Niamh MadiganSolving solubility problems is one of the leading challenges in drug development, as poorly soluble compounds are estimated to account for 60% of compounds. Preclinical development encompasses the a...
Steps to Expediting Time-to-Market for Insoluble Drug Candidates
March 15 by Niamh MadiganImproving the solubility of new chemical entities has proven to be one of the biggest hurdles to overcome in pharmaceutical drug development, and companies are always looking for new strategies for...
How to Predict the Absorption Rate of New Chemical Entities
February 23 by Pharmaceuticals & Biotechnology EditorCurrent estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory B...
Maximizing Bioavailability and Expediting Time-to-Market for Poorly Soluble Drug Candidates
February 02 by Pharma IQPoorly soluble candidates now account for 60 percent of drugs in the pipeline, and as technologies become more complex, the figure continues to increase. Pharmaceutical companies are now stepping...
Does Your Bioavailability Need a Boost?
March 29 by Pharma IQOne of the major drug development hurdles is poor solubility, an estimated 40 percent of drugs are poorly soluble or insoluble in water1. As a result, a number of companies and partne...
Spray-Dried Dispersion Technology: Solving Drug Solubility Challenges
March 09 by Amber ScorahAmorphous spray dried dispersions (SDDs) have emerged as a broadly applicable technology for the delivery of poorly soluble drug molecules. Methods for formulating and predicting the physical stabilit...
3 Tips on Overcoming Poor Aqueous Solubility and Stability
February 15 by Helen WinsorWhat are the 7 Deadly Sins of Quality Assurance and Quality Control? Download our free QA QC eBook now to find out! Rene Holm, Head of Preformulation at H L...
Investing in Techniques for Developing Amorphous Materials
February 13 by Pharma IQThe use of amorphous materials presents many opportunities for the pharmaceutical industry in terms of increased solubility and bioavailability, particularly as a growing number of insoluble active ph...